Document Detail


Prasugrel vs. Clopidogrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Model-Based Cost-Effectiveness Analysis for Germany, Sweden, the Netherlands, and Turkey.
MedLine Citation:
PMID:  23339464     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Abstract Objective: To evaluate the long-term cost-effectiveness of 12-months treatment with prasugrel versus clopidogrel from four European healthcare systems' perspectives (Germany, Sweden, the Netherlands, and Turkey). Methods: In the TRITON-TIMI 38 trial, patients with an acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) were treated with prasugrel or clopidogrel. Prasugrel reduced the composite endpoint (cardiovascular death, MI, or stroke), but increased TIMI major bleeding. A Markov model was constructed to facilitate a lifetime horizon for the analysis. A series of risk equations constructed using individual patient data from TRITON-TIMI 38 was used to estimate risks of clinical events. Quality-adjusted life-years (QALYs) were derived by weighting survival time by estimates of health related quality of life. Incremental cost-effectiveness is presented based on differences in treatments' mean costs and QALYs for the licensed population in TRITON-TIMI 38, and the sub-groups of UA-NSTEMI, STEMI, diabetes, and the 'core clinical cohort' (<75 years, ≥60kg, no history of stroke or TIA). Results: Mean cost of study drug was €364 (Turkey) to €818 (Germany) higher for prasugrel vs. clopidogrel. Rehospitalisation costs at 12 months were lower for prasugrel due to reduced rates of revascularisation, though hospitalisation costs beyond 12 months were higher due to longer life expectancy associated with lower rates of non-fatal MI in the prasugrel group. The incremental cost per QALY saved with prasugrel in the licensed population ranged from €6,520 (for Sweden) to €14,350 for (Germany). Prasugrel's cost per QALY was more favourable still in the STEMI and diabetes sub-groups of the licensed population. Limitations: Probabilistic analyses of the whole trial population is impractical due to the number of individual patient profiles over which population level results are calculated. Conclusion: Among patients undergoing PCI for ACS, treatment with prasugrel compared with clopidogrel resulted in favourable cost-effectiveness profiles from these healthcare systems' perspectives.
Authors:
Andrew Davies; Ameet Bakhai; Claude Schmitt; Annabel Barrett; Peita Graham-Clarke; Mark Sculpher
Related Documents :
18053374 - Use of octreotide for the prevention of pancreatic fistula after elective pancreatic su...
7498684 - Endoscopic transpapillary drainage of pancreatic pseudocysts.
16843734 - Role of early multisystem organ failure as major risk factor for pancreatic infections ...
24040944 - Minimally invasive sacroiliac joint fusion: one-year outcomes in 18 patients.
8166904 - Arthroscopic subacromial decompression and rotator cuff debridement for stage ii and st...
10750774 - Ultra fast track in elective congenital cardiac surgery.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-22
Journal Detail:
Title:  Journal of medical economics     Volume:  -     ISSN:  1941-837X     ISO Abbreviation:  J Med Econ     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9892255     Medline TA:  J Med Econ     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  High levels of mortality, malnutrition, and measles, among recently-displaced Somali refugees in Dag...
Next Document:  Healthcare resource utilization and economic impact of a ?2 g/dL decrease in hemoglobin in osteoarth...